Check each statement against experiments, exact results, and limitations, with provenance intact.Know what the science actually supports before you trust the answer.
Press Enter ↵ to review paper
Explore by Goal
"We are just an advanced breed of monkeys on a minor planet of a very average star. But we can understand the Universe. That makes us something very special."
- Stephen Hawking
Quick Explanation
Copied
Skeptical take
NIH/HHS is proposing tighter, more specific ClinicalTrials.gov registration + results requirements (via an NPRM) to reduce reporting distortions and to improve the usefulness of public trial results—but the paper is largely a policy rationale rather than an empirical test of real-world impact.
Long Explanation
Paper Review (Critical): Proposed Rule for U.S. Clinical Trial Registration & Results Submission
Deborah A. Zarin, Tony Tse, Jerry Sheehan — NEJM, published Dec 24, 2014; paper DOI: 10.1056/NEJMsr1414226
What the paper is doing (visual first)
Diagram derived from the paper’s descriptions of FDAAA, the HHS NPRM, and draft NIH/ICMJE policies, and the argued mechanism linking improved reporting to reduced distortions and better use of trial results.
Core scientific/technical content (as the paper presents it)
1) Scope and definitions: “applicable clinical trial” & related exclusions
The paper emphasizes that the FDAAA/NPRM framework is not limited to a narrow subset (e.g., it addresses multiple trial types involving FDA-regulated drugs/biologics/devices and certain controlled trials, and excludes only specific categories like phase 1 drug trials and small feasibility trials of devices as described by FDA regulations).
It also highlights the role of ClinicalTrials.gov registration at initiation for mitigating publication/reporting biases, noting that results availability has remained uneven even when existence of trials is easier to know.
2) What counts as “results”: aggregate/sum tables, not participant-level data
The paper repeatedly stresses that FDAAA/NPRM reporting is designed around summary (aggregate) results submitted to ClinicalTrials.gov, rather than individual participant data.
The NPRM proposals (as summarized) seek to define “primary” outcomes (e.g., those specified in the power calculation) and characterize “secondary” outcomes as prespecified outcomes with a specific analysis plan, and it proposes more precise outcome-measure descriptions including measurement, metric, and time frame.
The paper states that since September 2009 results submissions to ClinicalTrials.gov must include tables for serious adverse events (by study group) and other adverse events exceeding a 5% frequency threshold, and that the NPRM proposes minor modifications while soliciting comment on adding additional information (e.g., time frames of AE data collection, systematic vs nonsystematic collection approach, all-cause mortality tables, and sponsor/investigator attribution of AEs to the intervention).
The paper describes an HHS proposal to require submission of results for applicable clinical trials of unapproved products to reduce bias from selective disclosure, assist benefit–harm assessment across drug/device classes, avoid duplication of trials once unsafe/ineffective, and support informed consent risk–benefit descriptions for future studies.
What’s strong vs what’s missing (skeptical critique)
Strengths
Clear mapping from problem → proposed reporting mechanism. The paper argues that structured, more specific public results (outcomes and AE tables) can improve cross-trial comparison and reduce selective result disclosure distortions.
Specificity focus (outcome definitions + AE table structure). By describing proposed definitions and requiring more precise outcome measurement descriptors, the paper targets a concrete failure mode of registries/results databases: vague or insufficiently comparable outcome entries.
Limitations / blind spots
Policy rationale without a direct empirical “effectiveness test”. The paper is not presented as a field study comparing pre/post outcomes of the NPRM proposals; it states expected benefits.
Compliance feasibility and data-quality variation are not quantified here. The paper highlights structural improvements, but it does not quantify how reliably sponsors will populate the added fields (or how to measure “quality” vs “completeness” once requirements change).
AE attribution subjectivity is explicitly acknowledged as potentially controversial, but remains a proposed/optional area. The paper notes lack of consensus about the value of subjective judgments for summary reporting after trial completion.
Counterpoints: what could fail even if the rule is adopted?
Even with clearer outcome and AE fields, reporting bias could persist if sponsors selectively choose which outcomes to label as primary/secondary or if “specificity” improves metadata but not substantive result completeness. The paper discusses definitions and specificity proposals, but in the provided text it does not supply a measurement framework for detecting such strategic labeling or post-hoc outcome re-specification.
Practical takeaways (what to use as a researcher)
Use the paper as a checklist for what structured fields should exist in ClinicalTrials.gov results: participant flow and demographics, prespecified outcome measures (with measurement/metric/time specificity), and AE tables with serious and frequency-thresholded adverse events.
When interpreting public results databases, treat outcome-label metadata as a necessary but not sufficient condition for analytic validity: the paper motivates specificity requirements because vague entries impede comparison.
Paper-level citation integrity note
In this review, I used only bibliographic claims that are directly supported by the provided full-text excerpt; therefore most claims are anchored to the NEJM article DOI (10.1056/NEJMsr1414226).
Feedback:
Updated: May 01, 2026
BGPT Paper Review
Study Novelty
40%
The paper’s core content is a structured policy summary of an NPRM building on FDAAA and existing registration/reporting norms, rather than a novel empirical scientific method.
Scientific Quality
60%
Scientific quality is limited by its non-empirical, rationale-driven structure: it describes proposed requirements and expected benefits, but the excerpt does not provide causal evidence, quantified audit metrics, or direct measurement of downstream improvements. It does, however, provide internally consistent technical detail on what fields/definitions are proposed (primary/secondary outcomes and AE table handling).
Study Generality
70%
The underlying idea—standardized, specific public reporting to mitigate selective reporting distortions—has broad applicability across intervention trials, but the paper is grounded in U.S. regulatory mechanisms and ClinicalTrials.gov structures.
Study Usefulness
70%
For researchers and evidence synthesizers, it provides a practical conceptual checklist of what registration/results structures the NPRM aims to enforce (outcome specificity and AE table content).
Study Reproducibility
30%
There is no computational pipeline, dataset, or experimental protocol to reproduce; it is a policy proposal summary.
Explanatory Depth
50%
It explains the expected causal pathway at a conceptual level (structured reporting → reduced reporting bias → better analyses), but does not present mechanistic empirical validation for how specific proposed fields will change sponsor behavior or analytic validity.
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
The hypothesis that adding outcome specificity fields alone will eliminate selective reporting is unlikely: the paper acknowledges variability in reporting practices and the lack of an empirical evaluation of the NPRM’s causal impact, implying other mechanisms of distortion could persist.
The hypothesis that sponsor-investigator causality attribution will become consistently decision-useful across trials is doubtful because the paper explicitly notes lack of consensus about its value for summary reporting.
Science Art
Science Movie
Make a narrated HD Science movie for this answer ($32 per minute)
Discussion
Stay current without chasing every paper.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.
Explore by Goal
Quick Explanation
Long Explanation
Top Data Sources
Ask a Follow-Up
Key Insight
Hypothesis Graveyard
Discussion
My BGPT